Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005

Firms release positive survival data from pivotal trial of Tarceva in combination with Lilly’s Gemzar. Investigators believe pancreatic cancer is a “logical place to look” for expanded use of EGFR inhibitors like Tarceva.